This segment focuses on the research, development, production, and sales of a comprehensive range of blood-derived products. These include human albumin, intravenous human immunoglobulin (IVIG), rabies immunoglobulin, human fibrinogen, and hepatitis B human immunoglobulin. R&D efforts are directed towards improving the safety, efficacy, and yield of these products, as well as developing new formulations and applications. The segment addresses critical patient needs in areas such as immunodeficiency, infectious diseases, and trauma. China Resources Boya leverages advanced fractionation and purification technologies to ensure high-quality products. Future opportunities include expanding the product pipeline with novel immunoglobulin therapies and exploring new markets.

This segment is dedicated to the development, manufacturing, and commercialization of pharmaceutical products for the treatment of diabetes. The product portfolio includes metformin hydrochloride tablets/enteric-coated tablets, pioglitazone hydrochloride dispersible tablets, glimepiride tablets, and calcium dobesilate capsules. Research and development activities focus on improving drug delivery systems, enhancing therapeutic efficacy, and reducing side effects. The segment aims to address the growing prevalence of diabetes and improve the quality of life for patients. China Resources Boya employs advanced pharmaceutical technologies to ensure product quality and consistency. Future opportunities include developing innovative combination therapies and exploring personalized medicine approaches for diabetes management.

This segment encompasses the research, development, production, and sales of a diverse range of biochemical and chemical medicines. The product portfolio includes compound osteotide, oxytocin, and heparin sodium injections, targeting various therapeutic areas such as medicine, hepatitis, gynecology, and immunomodulation. R&D efforts are focused on developing novel formulations, improving drug delivery systems, and expanding the therapeutic applications of existing products. The segment aims to address unmet medical needs and improve patient outcomes across a broad spectrum of diseases. China Resources Boya leverages advanced chemical synthesis and bioprocessing technologies to ensure product quality and efficacy. Future opportunities include developing innovative therapies for chronic diseases and exploring new markets.